Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 2.12 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
Gulf Pharmaceutical Industries PSC has a Altman Z-Score of 2.15, indicating it is in Grey Zones. This implies that Gulf Pharmaceutical Industries PSC is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADX:JULPHAR vs MCK, CAH, COR: Altman Z-Score Comparison
For the Medical Distribution subindustry, Gulf Pharmaceutical Industries PSC's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gulf Pharmaceutical Industries PSC Altman Z-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Gulf Pharmaceutical Industries PSC's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Gulf Pharmaceutical Industries PSC's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a Altman Z-Score of 2.15 as of Jul. 24, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. This is 42% above median its historical median of 1.51. According to the industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #73 out of 119 companies in the Medical Distribution industry, placing it in the top 61.3%.
Is Gulf Pharmaceutical Industries PSC's Altman Z-Score too high?
Gulf Pharmaceutical Industries PSC's current Altman Z-Score of 2.15 is 42% above median its 10-year median of 1.51. The Medical Distribution industry median Altman Z-Score is 2.59. Gulf Pharmaceutical Industries PSC's value of 2.15 is 17% below this industry median. Based on the distribution chart, Gulf Pharmaceutical Industries PSC ranks #73 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's Altman Z-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #73 out of 119 companies for Altman Z-Score. This places Gulf Pharmaceutical Industries PSC in the lower half of its industry. The industry median Altman Z-Score is 2.59. Gulf Pharmaceutical Industries PSC's value of 2.15 is 17% below this benchmark. While the company's 10-year median is 1.51 vs. the industry median of 2.59, Gulf Pharmaceutical Industries PSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Distribution company?
The median Altman Z-Score among Medical Distribution companies is 2.59, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gulf Pharmaceutical Industries PSC's current Altman Z-Score of 2.15 is 17% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. For the Medical Distribution industry, the median Altman Z-Score is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gulf Pharmaceutical Industries PSC's current Altman Z-Score is 2.15, which is 42% above median its own 10-year median of 1.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.09, compared to a current price of د.إ1.04 — trading 4.6% below its estimated fair value. The current Altman Z-Score is 2.15, which is 42% above median its 10-year median of 1.51 and 17% below the Medical Distribution industry median of 2.59. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current Altman Z-Score is 2.15 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued.
The current stock price of د.إ1.04 is trading 4.6% below its estimated GF Value™ of د.إ1.09.
GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.
Key valuation signals for ADX:JULPHAR:
Altman Z-Score: 2.15 (42% above median its 10-year median of 1.51)
GF Value™: د.إ1.09 vs. price of د.إ1.04 (4.6% below fair value)
Industry Position: 17% below the Medical Distribution median (#73 of 119)
No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gulf Pharmaceutical Industries PSC Business Description
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
54GF Score
Get the complete analysis for ADX:JULPHAR
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADX:JULPHAR has been successfully added to your 
